Department of Medicine

University of Pittsburgh

Hussein Tawbi, MD, PhD


Associate Professor of Medicine

UPCI Melanoma and Skin Cancer Program

Co-Director, UPCI Sarcoma Program

Director, UPCI-CTRC

Office: UPMC Cancer Pavilion, Suite 548
5150 Centre Avenue
Pittsburgh, PA 15232
Phone: 412-648-6578
Fax: 412-648-6579
Find A Doctor UPMC Profile

B.Sc. in Chemistry, American University of Beirut, 1997
MD, American University of Beirut, 2001
MSc in Clinical/Translational Research, University of Pittsburgh, 2007
PhD, University of Pittsburgh, 2011

Internship in Internal Medicine, American University of Beirut Medical Center, 2002
Residency in Internal Medicine, Univeristy of Pittsburgh Medical Center, 2005
Fellowship in Hematology/Oncology, University of Pittsburgh Cancer Institute, 2007
Fellowship Training in Sarcoma, University of Michigan, 2007

Area of Specialization/Research Interest  
Chemotherapy Resistance in Metastatic Melanoma
Epigenetic Regulation of DNA Repair Mechanisms in Melanoma
Early Phase Clinical Trials
BRAF Inhibitor Resistance in Metastatic Melanoma
Melanoma Brain Metastases

Dr. Tawbi received his MD in 2001 from the American University of Beirut, Beirut, Lebanon; completed his training in Internal Medicine and Hematology/Oncology at the University of Pittsburgh; and joined the faculty ranks at the University of Pittsburgh School of Medicine as an Assistant Professor in 2007. Dr. Tawbi's clinical training was coupled with formal instruction in Clinical and Translational Research that culminated in a PhD degree in Clinical and Translational Science in 2011. Dr. Tawbi also holds a secondary appointment at the University of Pittsburgh Clinical and Translational Science Institute (CTSI) as Assistant Professor of Clinical and Translational Science.

The primary focus of Dr. Tawbi's research has been early phase studies of novel agents in melanoma and sarcoma. Dr. Tawbi designed, and conducted several Phase I and Phase II studies in both diseases. Dr. Tawbi has been involved in the ECOG-ACRIN effort as a member of the Melanoma Committee and Liaison with both the Developmental Therapeutics (DT) Committee and Biomarkers Steering Committee. Dr. Tawbi also served as PI for national studies such as the NCI- Organ Dysfunction Working Group (NCI-ODWG) study of the PARP inhibitor ABT-888 alone and in combination with carboplatin and paclitaxel in patients with varying degrees of hepatic and renal dysfunction (NCI protocol-8808).

Dr. Tawbi holds numerous memberships in professional societies such as the American Board of Internal Medicine, member of the American Society of Clinical Oncology (ASCO), member of the Society for Clinical and Translational Science, member of the Society for Translational Oncology, member of the Steering Committee of Clinical Trial Management Application - UPCI, member of the UPMC EMR physician consultant group, and member of the University of Pittsburgh Hematology/Oncology Fellowship Curriculum Committee.

Dr. Tawbi is well-published in peer-reviewed literature in such outstanding journals as the Journal of Clinical Oncology, Annals of Oncology, Lancet Oncology, and Cancer.

For Pub Med search results, click here.